| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED TRIPLE-NEGATIVE OR HORMONE RECEPTOR-LOW/HER2-NEGATIVE BREAST CANCER |
III |
in corso |
CARCINOMA MAMMARIO |
- SC Oncologia Clinica Sperimentale di Senologia |
|
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) |
III |
in corso |
CANCRO PROSTATA |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
Studio non interventistico, multicentrico, prospettico, osservazionale sull’efficacia del Tucatinib in associazione a Capecitabina e Trastuzumab nel trattamento real-life di pazienti con cancro alla mammella metastatico HER2-positivo: Studio THERapy |
NA |
in corso |
CARCINOMA MAMMARIO |
SC Oncologia Clinica Sperimentale di Senologia - |
|
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF VOLRUSTOMIG (MEDI5752) AS SEQUENTIAL THERAPY VERSUS OBSERVATION IN PARTICIPANTS WITH UNRESECTED LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, WHO HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY |
III |
in corso |
CANCRO TESTA-COLLO |
- SC Oncologia Clinica Sperimentale Testa – Collo |
|
Studio di fase 2/3, randomizzato, in aperto su BT8009, in monoterapia o in combinazione, in partecipanti con carcinoma uroteliale localmente avanzato o metastatico (Duravelo-2) |
II/III |
in corso |
carcinoma uroteliale |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
